Reports third quarter revenue of $1.0 billion, GAAP net loss of $(0.2) billion and GAAP EPS of $(0.51) Narrows 2025 projected ...
Q3 earnings beat estimates but pipeline setback and lower 2025 guidance raise concerns. Full analysis of results and outlook.
Fintel reports that on November 10, 2025, B of A Securities maintained coverage of Moderna (NasdaqGS:MRNA) with a ...
Strong financial position with cash, cash equivalents and marketable securities of $93.7M Moderna litigation U.S. trial scheduled for March ...
A ruling in favour of the Trump administration could result in the president exercising “unusual” control over “routine” ...
After a generation of stagnation, interest in U.S. nuclear energy is sky high, thanks to artificial intelligence’s voracious ...
1hOpinion
AI promoted the CTO – and fired HR
Agentic AI isn’t your humdrum chatbot anymore: it’s autonomous decision-making algorithm that lives in workflows, interacts ...
Roivant Sciences Ltd.'s innovative model and breakthrough autoimmune drug pipeline make it a strong buy. Click here to read ...
Strong financial position with cash, cash equivalents and marketable securities of $93.7M Moderna litigation U.S. trial scheduled for March 2026;Favorable claim construction ruling in Pfizer-BioNTech ...
Q2 2026 Earnings Call Transcript November 10, 2025 Roivant Sciences Ltd. beats earnings expectations. Reported EPS is ...
The greater part of third quarter earnings results are in the rearview mirror. So far, the Q3 earnings season is off to a ...
Company reports Q3 2025 AUCATZYL® net product revenue of $21.1 million and deferred revenue of $7.6 million; 60 authorized treatment centers achieved ahead of targetClinical execution and data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback